UK Biobank

Touting their “commitment to openness,” AbbVie, Biogen and Pfizer last week launched a web-based tool giving access to results from analyses of whole exome sequencing data from 300,000 UK Biobank participants—producing “the world’s largest browsable resource linking rare protein-coding genetic variants to human health and disease,” according to a joint press release.

The initiative may also be an effort to comply with government- and Wellcome-backed Biobank requirements to share…

UK Biobank announced this week a joint initiative with GSK and Regeneron to develop genetic sequence data from 500,000 individuals that will be used to improve drug discovery and efficacy.

UK Biobank has been collecting health information and samples from participants in the United Kingdom for the past 10 years. Genetic sequencing will take place at the Regeneron Genetic Center in New York and the entire process is expected to cost $150 million and take 3–5 years to complete.

All…